John Gerecitano

Department of Oncology, Memorial Sloan Kettering Cancer Center

Affiliated withMemorial Sloan Kettering Cancer Center

Research Area

Biography

John Gerecitano has not added Biography.
If you are John Gerecitano and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 12	2014

Other Publications

Article	Year
Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation. Journal of hematotherapy & stem cell research\| PubMed ID: 12804180	2003
Treatment of Burkitt lymphoma in adults. Expert review of anticancer therapy\| PubMed ID: 16503854	2006
Novel small molecules in the treatment of lymphomas. Cancer treatment and research\| PubMed ID: 16704178	2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? British journal of haematology\| PubMed ID: 16882131	2006
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British journal of haematology\| PubMed ID: 19624539	2009
The future of small molecule inhibitors in lymphoma. Current oncology reports\| PubMed ID: 19679013	2009
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19903785	2009
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20068103	2010
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet. Oncology\| PubMed ID: 21094089	2010
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21346146	2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood\| PubMed ID: 22184409	2012
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study. Cancer\| PubMed ID: 22252775	2012
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma. British journal of haematology\| PubMed ID: 22533368	2012
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Investigational new drugs\| PubMed ID: 22615058	2013
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22825582	2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 23248254	2013
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortiu... Cancer\| PubMed ID: 24474568	2014
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert opinion on investigational drugs\| PubMed ID: 24669860	2014